MLLT1
MLLT1 (MLLT1 super elongation complex subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Wilms tumour and 1 more.
Overview
Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. Specifically recognises and binds acetylated and crotonylated histones, with a preference for histones that are crotonylated. Has a slightly higher affinity for binding histone H3 crotonylated at 'Lys-27' (H3K27cr) than 'Lys-20' (H3K9cr20).
Open Targets scores its association with cancer at 0.56 (direct and indirect evidence; datatypes literature 0.87, genetic association 0.14, somatic mutation 0.71). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Wilms' Tumour.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MLLT1 (MLLT1 super elongation complex subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Wilms tumour and 1 more.
- 1 · What it is
MLLT1 (MLLT1 super elongation complex subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Wilms tumour and 1 more.
- 2 · What goes wrong in cancer
Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA.
- 3 · How drugs use it
No product in this corpus aims at MLLT1 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:7134 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q03111 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000130382 (association with cancer (MONDO_0004992) 0.56; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.53, non-Hodgkin lymphoma 0.54, leukaemia 0.56 (GraphQL API, CC0)); IntOGen MLLT1 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. Specifically recognises and binds acetylated and crotonylated histones, with a preference for histones that are crotonylated. Has a slightly higher affinity for binding histone H3 crotonylated at 'Lys-27' (H3K27cr) than 'Lys-20' (H3K9cr20). May play a role in leukemogenic gene transcription. Acts as a key chromatin reader in acute myeloid leukaemia by recognising and binding to acetylated histones via its YEATS domain, thereby regulating oncogenic gene transcription. Location: Nucleus (UniProt). Locus 19p13.3 (HGNC).
- Leukaemia: Open Targets association 0.56 with leukaemia (MONDO_0005059)
- Non-Hodgkin lymphoma: Open Targets association 0.54 with non-Hodgkin lymphoma (MONDO_0018908)
- Wilms tumour: IntOGen driver in 1 cohort (WT)
- Acute lymphoblastic leukaemia: Open Targets association 0.53 with acute lymphoblastic leukaemia (MONDO_0004967)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"MLLT1" OR ABSTRACT:"MLLT1" OR TITLE:"MLLT1 super elongation complex subunit" OR ABSTRACT:"MLLT1 super elongation complex subunit" OR TITLE:"LTG19" OR ABSTRACT:"LTG19" OR TITLE:"YEATS1" OR ABSTRACT:"YEATS1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MLLT1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetZMYM2
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, IntOGen.
- TargetAFF1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, IntOGen.
- TargetRPL10
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, IntOGen.
- TargetARID5B
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Open Targets Platform.
- TargetBAK1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Open Targets Platform.
- TargetCEP43
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Open Targets Platform.
- TargetGNB1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Open Targets Platform.
- TargetPPAT
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Open Targets Platform.